Pharmaceutical intelligence for Sichuan Baili Pharmaceutical with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Assets: 1

Recent signals(1)

ClinicalJuly 25, 2026

Phase II Study of BL-B01D1 with PD-1 Antibody in Advanced Lung Cancer and Other Tumors

A phase II clinical trial is underway to evaluate the efficacy and safety of BL-B01D1 in combination with PD-1 monoclonal antibody.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity

No signals indexed for this entity yet.

Clinical activity(1)

ClinicalJuly 25, 2026

Phase II Study of BL-B01D1 with PD-1 Antibody in Advanced Lung Cancer and Other Tumors

A phase II clinical trial is underway to evaluate the efficacy and safety of BL-B01D1 in combination with PD-1 monoclonal antibody.

Competitive activity

No signals indexed for this entity yet.

Assets

Phase →

Therapeutic areas

Non-small Cell Lung Cancer →

Oncology →

Indications

Non-small Cell Lung Cancer →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.